Association study of AGER gene polymorphism and hypertension in Han Chinese population

Gene

Volumn 498, Issue 2, 2012, Pages 311-316

  Yang, Song ^a   Wang, Hairu ^b   Yang, Yichun ^a   Wang, Wen ^a   Jiang, Jiandong ^a   Zhao, Xianghai ^a   Du, Qinglian ^a   Wang, Xuecai ^a   Yao, Yingshui ^c   Shen, Hongbing ^b   Shen, Chong ^b   Zhao, Yanping ^a  

^a YIXING PEOPLE S HOSPITAL   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

^c WANNAN MEDICAL COLLEGE   (China)

Author keywords

Advanced glycation end products; Association study; Hypertension; Receptor of advanced glycation end products

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR;

ARTICLE; BLOOD PRESSURE; CHINESE; CORRELATION ANALYSIS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HYPERTENSION; PRIORITY JOURNAL; RISK ASSESSMENT;

ADOLESCENT; ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD PRESSURE; CASE-CONTROL STUDIES; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, IMMUNOLOGIC; YOUNG ADULT;

EID: 84862803283     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2012.01.080     Document Type: Article

References (44)

1. Bierhaus A., Hofmann M.A., Ziegler R., Nawroth P.P. AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. Cardiovasc. Res. 1998, 37:586-600.
2. Bierhaus A., Humpert P.M., Morcos M., Wendt T., Chavakis T., Arnold B., Stern D.M., Nawroth P.P. Understanding RAGE, the receptor for advanced glycation end products. J. Mol. Med. 2005, 83:876-886.
3. Bohlender J., Franke S., Sommer M., Stein G. Advanced glycation end products: a possible link to angiotensin in an animal model. Ann. N. Y. Acad. Sci. 2005, 1043:681-684.
4. Cantor R.M., Lange K., Sinsheimer J.S. Prioritizing GWAS results: a review of statistical methods and recommendations for their application. Am. J. Hum. Genet. 2010, 86:6-22.
5. Dao H.H., Essalihi R., Bouvet C., Moreau P. Evolution and modulation of age-related medial elastocalcinosis: impact on large artery stiffness and isolated systolic hypertension. Cardiovasc. Res. 2005, 66:307-317.
6. de Bakker P.I., Ferreira M.A., Jia X., Neale B.M., Raychaudhuri S., Voight B.F. Practical aspects of imputation-driven meta-analysis of genome-wide association studies. Hum. Mol. Genet. 2008, 17:R122-R128.
7. dos Santos K.G., Canani L.H., Gross J.L., Tschiedel B., Pires Souto K.E., Roisenberg I. The -374A allele of the receptor for advanced glycation end products gene is associated with a decreased risk of ischemic heart disease in African-Brazilians with type 2 diabetes. Mol. Genet. Metab. 2005, 85:149-156.
8. Falcone C., Geroldi D., Buzzi M.P., Emanuele E., Yilmaz Y., Fontana J.M., Vignali L., Boiocchi C., Sbarsi I., Cuccia M. The -374T/A RAGE polymorphism protects against future cardiac events in nondiabetic patients with coronary artery disease. Arch. Med. Res. 2008, 39:320-325.
9. Farmer D.G., Kennedy S. RAGE, vascular tone and vascular disease. Pharmacol. Ther. 2009, 124:185-194.
10. Gao J., Shao Y., Lai W., Ren H., Xu D. Association of polymorphisms in the RAGE gene with serum CRP levels and coronary artery disease in the Chinese Han population. J. Hum. Genet. 2010, 55:668-675.
11. Grossin N., Boulanger E., Wautier M.P., Wautier J.L. The different isoforms of the receptor for advanced glycation end products are modulated by pharmacological agents. Clin. Hemorheol. Microcirc. 2010, 45:143-153.
12. Hallam K.M., Li Q., Ananthakrishnan R., Kalea A., Zou Y.S., Vedantham S., Schmidt A.M., Yan S.F., Ramasamy R. Aldose reductase and AGE-RAGE pathways: central roles in the pathogenesis of vascular dysfunction in aging rats. Aging Cell 2010, 9. 776-684.
13. Hartog J.W., van de Wal R.M., Schalkwijk C.G., Miyata T., Jaarsma W., Plokker H.W., van Wijk L.M., Smit A.J., van Veldhuisen D.J., Voors A.A. Advanced glycation end-products, anti-hypertensive treatment and diastolic function in patients with hypertension and diastolic dysfunction. Eur. J. Heart Fail. 2010, 12:397-403.
14. Kalousova M., Zima T., Tesar V., Dusilova-Sulkova S., Skrha J. Advanced glycoxidation end products in chronic diseases-clinical chemistry and genetic background. Mutat. Res. 2005, 579:37-46.
15. Koyama H., Yamamoto H., Nishizawa Y. Endogenous secretory RAGE as a novel biomarker for metabolic syndrome and cardiovascular diseases. Biomark. Insight 2007, 2:331-339.
16. Koyama H., Yamamoto H., Nishizawa Y. RAGE and soluble RAGE: potential therapeutic targets for cardiovascular diseases. Mol. Med. 2007, 13:625-635.
17. Lasky-Su J., Lyon H.N., Emilsson V., Heid I.M., Molony C., Raby B.A., Lazarus R., Klanderman B., Soto-Quiros M.E., Avila L., Silverman E.K., Thorleifsson G., Thorsteinsdottir U., Kronenberg F., Vollmert C., Illig T., Fox C.S., Levy D., Laird N., Ding X., McQueen M.B., Butler J., Ardlie K., Papoutsakis C., Dedoussis G., O'Donnell C.J., Wichmann H.E., Celedon J.C., Schadt E., Hirschhorn J., Weiss S.T., Stefansson K., Lange C. On the replication of genetic associations: timing can be everything!. Am. J. Hum. Genet. 2008, 82:849-858.
18. Lunetta K.L., D'Agostino R.B., Karasik D., Benjamin E.J., Guo C.Y., Govindaraju R., Kiel D.P., Kelly-Hayes M., Massaro J.M., Pencina M.J., Seshadri S., Murabito J.M. Genetic correlates of longevity and selected age-related phenotypes: a genome-wide association study in the Framingham Study. BMC Med. Genet. 2007, 8(Suppl 1):S13.
19. Maeda S., Matsui T., Takeuchi M., Yamagishi S. Co-treatment with azelinidipine and olmesartan inhibits advanced glycation end products (AGEs) elicited down-regulation of adiponectin mRNA levels in cultured adipocytes partly via its anti-oxidative property. Int. J. Cardiol. 2011, 146:264-266.
20. Matsui T., Yamagishi S., Takeuchi M., Ueda S., Fukami K., Okuda S. Nifedipine inhibits advanced glycation end products (AGEs) and their receptor (RAGE) interaction-mediated proximal tubular cell injury via peroxisome proliferator-activated receptor-gamma activation. Biochem. Biophys. Res. Commun. 2010, 398:326-330.
21. McEniery C.M., Wilkinson I.B., Avolio A.P. Age, hypertension and arterial function. Clin. Exp. Pharmacol. Physiol. 2007, 34:665-671.
22. Mizutani K., Ikeda K., Tsuda K., Yamori Y. Inhibitor for advanced glycation end products formation attenuates hypertension and oxidative damage in genetic hypertensive rats. J. Hypertens. 2002, 20:1607-1614.
23. Nakamura K., Adachi H., Matsui T., Kurita Y., Takeuchi M., Yamagishi S. Independent determinants of soluble form of receptor for advanced glycation end products in elderly hypertensive patients. Metabolism 2009, 58:421-425.
24. Percy C.J., Brown L., Power D.A., Johnson D.W., Gobe G.C. Obesity and hypertension have differing oxidant handling molecular pathways in age-related chronic kidney disease. Mech. Ageing Dev. 2009, 130:129-138.
25. Perloff D., Grim C., Flack J., Frohlich E.D., Hill M., McDonald M., Morgenstern B.Z. Human blood pressure determination by sphygmomanometry. Circulation 1993, 88:2460-2470.
26. Ramasamy R., Yan S.F., Schmidt A.M. RAGE: therapeutic target and biomarker of the inflammatory response-the evidence mounts. J. Leukoc. Biol. 2009, 86:505-512.
27. Safar M.E., Lajemi M., Rudnichi A., Asmar R., Benetos A. Angiotensin-converting enzyme D/I gene polymorphism and age-related changes in pulse pressure in subjects with hypertension. Arterioscler. Thromb. Vasc. Biol. 2004, 24:782-786.
28. Satagopan J.M., Elston R.C. Optimal two-stage genotyping in population-based association studies. Genet. Epidemiol. 2003, 25:149-157.
29. Satagopan J.M., Venkatraman E.S., Begg C.B. Two-stage designs for gene-disease association studies with sample size constraints. Biometrics 2004, 60:589-597.
30. Sawabe M. Vascular aging: from molecular mechanism to clinical significance. Geriatr. Gerontol. Int. 2010, 10(Suppl 1):S213-S220.
31. Schmidt A.M., Hori O., Brett J., Yan S.D., Wautier J.L., Stern D. Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. Arterioscler. Thromb. 1994, 14:1521-1528.
32. Schmidt A.M., Yan S.D., Yan S.F., Stern D.M. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J. Clin. Invest. 2001, 108:949-955.
33. Semba R.D., Najjar S.S., Sun K., Lakatta E.G., Ferrucci L. Serum carboxymethyl-lysine, an advanced glycation end product, is associated with increased aortic pulse wave velocity in adults. Am. J. Hypertens. 2009, 22:74-79.
34. Shen C., Lu X., Li Y., Zhao Q., Liu X., Hou L., Wang L., Chen S., Huang J., Gu D. Emilin1 gene and essential hypertension: a two-stage association study in northern Han Chinese population. BMC Med. Genet. 2009, 10:118.
35. Shi G., Gu C.C., Kraja A.T., Arnett D.K., Myers R.H., Pankow J.S., Hunt S.C., Rao D.C. Genetic effect on blood pressure is modulated by age: the Hypertension Genetic Epidemiology Network Study. Hypertension 2009, 53:35-41.
36. Staessen J.A., Wang J., Bianchi G., Birkenhager W.H. Essential hypertension. Lancet 2003, 361:1629-1641.
37. Steckelings U.M., Rompe F., Kaschina E., Unger T. The evolving story of the RAAS in hypertension, diabetes and CV disease: moving from macrovascular to microvascular targets. Fundam. Clin. Pharmacol. 2009, 23:693-703.
38. Stitt A.W., Burke G.A., Chen F., McMullen C.B., Vlassara H. Advanced glycation end-product receptor interactions on microvascular cells occur within caveolin-rich membrane domains. FASEB J. 2000, 14:2390-2392.
39. van Zoelen M.A., Yang H., Florquin S., Meijers J.C., Akira S., Arnold B., Nawroth P.P., Bierhaus A., Tracey K.J., van der Poll T. Role of Toll-like receptors 2 and 4, and the receptor for advanced glycation end products (RAGE) in Hmgb1 induced inflammation in vivo. Shock 2008, 31:280-284.
40. Volz H.C., Kaya Z., Katus H.A., Andrassy M. The role of HMGB1/RAGE in inflammatory cardiomyopathy. Semin. Thromb. Hemost. 2010, 36:185-194.
41. Yamagishi S., Nakamura K., Matsui T., Ueda S., Fukami K., Okuda S. Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complications. ExpertOpin. Investig. Drugs 2008, 17:983-996.
42. Yan S.F., Ramasamy R., Schmidt A.M. Receptor for AGE (RAGE) and its ligands-cast into leading roles in diabetes and the inflammatory response. J. Mol. Med. 2009, 87:235-247.
43. Yao D., Brownlee M. Hyperglycemia-induced reactive oxygen species increase expression of the receptor for advanced glycation end products (RAGE) and RAGE ligands. Diabetes 2010, 59:249-255.
44. Yuan H.Y., Chiou J.J., Tseng W.H., Liu C.H., Liu C.K., Lin Y.J., Wang H.H., Yao A., Chen Y.T., Hsu C.N. FASTSNP: an always up-to-date and extendable service for SNP function analysis and prioritization. Nucleic Acids Res. 2006, 34:W635-W641.